个人简介
马航，男，1993.06—，医学博士，副教授，硕士研究生导师。主要从事黄连等传统道地药材物质基础和作用机制研究工作，以及中药活性成分在中医优势病种中的开发应用、结合计算机技术的的中医药机理阐释。
学习及工作经历
2011.09-2015.06，重庆大学，制药工程，学士
2015.09-2018.06，西南大学，中药学，硕士
2018.09-2022.06，上海交通大学，药学，博士
2022.07-至今，西南大学，药学院，副教授
联系方式
hangma@swu.edu.cn
科技获奖
2023年重庆市科技进步一等奖，黄连产业化关键技术攻关与示范推广应用，5/15
主持项目
1. 中央本级重大增减支项目，基于4个高质量基因组的多组学研究揭示我国黄连的道地性形成机制，2024.01-2025.12
2. 国家自然科学基金青年项目，基于脲酶结构“敏感点”研究表小檗碱治疗H. pylori不产生耐药的机制，2024.01-2026.12
3. 云南省院士专家工作站技术开发，胡黄连指纹图谱分析及质量控制研究，2022.09-2025.09
4. 中央高校基本科研业务费，黄连生物碱抗H. pylori耐药及作用机制研究，2023.01-2025.12
主要代表论文
1. Xiong M, Chen X, Wang H, Tang X, Wang Q, Li X, Ma H*, Ye X*, Combining transcriptomics and network pharmacology to reveal the mechanism of Zuojin capsule improving spasmolytic polypeptide-expressing metaplasia. J Ethnopharmacol, 2024, 318(Pt B):117075.
2. Wu H1, Xie X1, Tang Q, Huang T, Tang X, Jiao B, Wang R, Zhu X, Ye X*, Ma H*, Li X*. Epiberberine inhibits Helicobacter pylori and reduces host apoptosis and inflammatory damage by down-regulating urease expression. J Ethnopharmacol, 2024, 318(Pt B):117046.
3. Li M, Yang J, Li J, Zhou Y, Li X, Ma Z, Li X, Ma H*, Ye X*. Epiberberine induced p53/p21-dependent G2/M cell cycle arrest and cell apoptosis in gastric cancer cells by activating γ-aminobutyric acid receptor- β3. Phytomedicine, 2024, 123:155198.
4. Tang Q, Ma Z, Tang X, Liu Y, Wu H, Peng Y, Jiao B, Wang R, Ye X*, Ma H*, Li X*. Coptisine inhibits Helicobacter pylori and reduces the expression of CagA to alleviate host inflammation in vitro and in vivo.J Ethnopharmacol, 2023, 314:116618.
5. He H, Chai X, Li J, Li C, Wu X, Ye X, Ma H*, Li X*. LCN2 contributes to the improvement of nonalcoholic steatohepatitis by 8-Cetylberberine, Life Sci, 2023, 321:121595.
6. Zhang J, Huang L, Tang X, Pan M, Ye X, Li X*, Ma H*. High β-Sitosterol-D-glucoside content in sweet potato varieties and its anti-breast cancer potential through multiple metastasis-associated signals. Food Science and Human Wellness, 2023, https://doi.org/10.26599/FSHW.2022.9250225
7. Gui Z, Li J, Li J, Li X, Chen L, Ma Z, Tang X, Gong X, Chai X, Lu F, Li M, Ma H*, Li X*, Ye X*. Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells. Chem Biol Interact, 2023, 374:110408.
8. Li X, Ma Z, Tang Q, Gui Z, Zhang B, Sun G, Li J, Li J, Li M, Li X, Ma H*, Ye X*. 8-octyl berberine combats Staphylococcus aureus by preventing peptidoglycan synthesis. Eur J Pharm Sci, 2023, 191:106602.
9. Hang Ma1, Yingying Guo1, Haoneng Tang1, et al., Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. Cell Discov, 8:16, 2022.
10. Hang Ma, Yang Yu, Meimei Wang, et al., Correlation between microbes and colorectal cancer: tumor apoptosis is induced by sitosterols through promoting gut microbiota to produce short-chain fatty acids. Apoptosis, 24:168–183, 2019.
11. Hang Ma1, Kai He1, Jianwei Zhu, et al., The anti-hyperglycemia effects of Rhizoma Coptidis alkaloids: A systematic review of modern pharmacological studies of the traditional herbal medicine. Fitoterapia, 134:210–220, 2019.
12. Hang Ma, Yinran Hu, Zongyao Zou, et al., Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice. Drug Development Research, 77:163–170, 2016.
社会兼职
中国中医药信息学会中医临床药学分会 常务理事
中华中医药学会中药化学分会 青年委员
